Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVT-100
- Development stage
- Phase 2
- Lead developer
- Microvascular Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MVT-100 is an investigational ultrasound contrast agent developed by Microvascular Therapeutics. It is a modified formulation of perflutren lipid microspheres, similar to the approved agent Definity but with a modified lipid blend (one lipid removed and another substituted). The agent is designed to improve the quality of echocardiograms in patients with suboptimal images by opacifying the left ventricular chamber and enhancing the delineation of the endocardial border. It is administered intravenously as a bolus or infusion and is currently being evaluated in Phase 1 clinical trials for safety and efficacy.
- Other names
- perflutren lipid microspheres
Beyond the preview
Go deeper on MVT-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVT-100.